Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-175-VII | HR+ | Luminal | GW843682X | PLK | PLK | 10642.139 | uM | inf | inf | 0.8856 | 0.8856 | 0.0000 | 0.0467 | 0.0078 | 0.7017 | |
| MDA-MB-134-VI | HR+ | Luminal | Dactolisib | PI3K | PI3K | 10998.155 | uM | inf | inf | 0.3974 | 0.3974 | 0.0000 | 0.2489 | 0.2687 | 0.9302 | |
| Hs 578T | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 7474.098 | uM | inf | inf | 1.0223 | 1.0223 | 0.0000 | -0.0080 | -0.0536 | 2.6093 | |
| BT-20 | TNBC | Basal A | PS-1145 | IKK | NFKB | 5902.065 | uM | inf | inf | 0.7265 | 0.7265 | 0.0000 | 0.1074 | 0.4823 | 1.2690 | |
| MDA-MB-134-VI | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 12206.154 | uM | inf | inf | 0.8646 | 0.8646 | 0.0000 | 0.0941 | 0.0903 | 1.0125 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 9469.026 | uM | inf | inf | 0.8847 | 0.8847 | 0.0000 | 0.0250 | 0.5685 | 1.2092 | |
| HCC38 | TNBC | Basal B | PD184352 | MEK | MAPK | 11850.155 | uM | inf | inf | 0.9060 | 0.9060 | 0.0000 | 0.0877 | 0.0000 | 2.1810 | |
| HCC1806 | TNBC | Basal A | MG-132 | Proteasome | Proteasome | 14128.189 | uM | inf | inf | -0.6315 | -0.6315 | 0.0000 | 0.4616 | 0.5621 | 2.7793 | |
| MDA-MB-436 | TNBC | Basal B | Trametinib | MEK | MAPK | 7902.05 | uM | inf | inf | 0.6492 | 0.6492 | 0.0000 | 0.1023 | 0.0604 | 1.8149 | |
| HCC38 | TNBC | Basal B | PS-1145 | IKK | NFKB | 7468.065 | uM | inf | inf | 0.8447 | 0.8447 | 0.0000 | 0.0735 | 0.5698 | 1.5219 | |
| LY2 | HR+ | Luminal | AG1024 | IGF1R | RTK | 10380.066 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0457 | -3.8399 | 1.2245 | |
| HCC38 | TNBC | Basal B | Ro 32-0432 | PKC | PKC | 10578.142 | uM | inf | inf | 0.9560 | 0.9560 | 0.0000 | 0.0618 | 0.0539 | 1.8112 | |
| CAMA-1 | HR+ | Luminal | Ribavirin | 15348.211 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0410 | -5.7835 | 0.7490 | |||
| MDA-MB-361 | HER2amp | Luminal | PD184352 | MEK | MAPK | 10999.155 | uM | inf | inf | 0.9030 | 0.9030 | 0.0000 | -0.0123 | -0.1189 | 0.7370 | |
| MDA-MB-175-VII | HR+ | Luminal | Purvalanol A | CDK1 | CDK | 7500.067 | uM | inf | inf | 1.0382 | 1.0382 | 0.0000 | 0.0025 | -0.0022 | 0.7143 | |
| 184A1 | NM | Basal | PD 98059 | MEK | MAPK | 12509.152 | uM | inf | inf | 0.7622 | 0.7622 | 0.0000 | 0.0595 | 0.4482 | 1.3755 | |
| LY2 | HR+ | Luminal | AG1024 | IGF1R | RTK | 7477.066 | uM | inf | inf | 0.2846 | 0.2846 | 0.0000 | 0.3601 | 0.3237 | 0.3409 | |
| BT-20 | TNBC | Basal A | TCS PIM-1 1 | Pim kinase | PIM | 11854.135 | uM | inf | inf | 0.8384 | 0.8384 | 0.0000 | 0.0710 | 0.5319 | 1.3170 | |
| HCC38 | TNBC | Basal B | L-779450 | BRAF | MAPK | 10578.137 | uM | inf | inf | 0.6868 | 0.6868 | 0.0000 | 0.0974 | 0.3820 | 1.8268 | |
| Hs 578T | TNBC | Basal B | Sirolimus | MTOR | MTOR | 7474.069 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0115 | -0.0565 | 2.5606 | |
| SUM149PT | TNBC | Basal B | GW-5074 | CRAF | MAPK | 7530.088 | uM | inf | inf | 1.0459 | 1.0459 | 0.0000 | -0.0231 | -0.8280 | 2.1310 | |
| MDA-MB-175-VII | HR+ | Luminal | Cetuximab | EGFR | ErbB | 7886.042 | uM | inf | inf | 0.9528 | 0.9528 | 0.0000 | -0.0085 | 0.3806 | 0.6462 | |
| CAMA-1 | HR+ | Luminal | MG-132 | Proteasome | Proteasome | 14236.189 | uM | inf | inf | -0.9745 | -0.9745 | 0.0000 | 0.7528 | 0.5730 | 0.8534 | |
| LY2 | HR+ | Luminal | Ribavirin | 15391.211 | uM | inf | inf | 0.9725 | 0.9725 | 0.0000 | 0.0076 | -0.0134 | 1.2835 | |||
| MCF 10A | NM | Basal B | PS-1145 | IKK | NFKB | 7485.065 | uM | inf | inf | 1.0111 | 1.0111 | 0.0000 | -0.0094 | -0.0465 | 3.5869 |